[1] [1] YAEGER R, CORCORAN R B. Targeting alterations in the RAF-MEK pathway［J］. Cancer Discovery, 2019, 9(3): 329-341.

[2] [2] ABERG E, PERANDER M, JOHANSEN B, et al. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4［J］. Journal of Biological Chemistry, 2006, 281(46): 35499-35510.

[3] [3] ROUSSEAU J, KLINGER S, RACHALSKI A, et al. Targeted inactivation of Mapk4 in mice reveals specific nonredundant functions of Erk3/Erk4 subfamily mitogen-activated protein kinases［J］. Molecular and Cellular Biology, 2010, 30(24): 5752-5763.

[4] [4] FENG Y, ZHANG L, WU J, et al. CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway［J］. Journal of Experimental & Clinical Cancer Research, 2019, 38(1): 54-70.

[5] [5] ZOU Zhengzhi, NIE Peipei, NI Yirong, et al. Thiostrepton induces autophagic cell death in non-small-cell lung cancer cells［J］. Acta Laser Biology Sinica, 2014, 23(1): 33-37.

[6] [6] CHEN P, LUO X, NIE P, et al. CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk［J］. Free Radical Biology and Medicine, 2017, 104(1): 280-297.

[7] [7] CHOI Y, KENDZIORSKI C. Statistical methods for gene set co-expression analysis［J］. Bioinformatics, 2009, 25(21): 2780-2786.

[8] [8] ZOU Z, YUAN Z, ZHANG Q, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells［J］. Autophagy, 2012, 8(12): 1798-1810.

[9] [9] WANG S M, ZOU Z Z, LUO X Y, et al. LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer［J］. Oncogene, 2018, 37(24): 3243-3259.

[10] [10] COHEN P A, JHINGRAN A, OAKNIN A, et al. Cervical cancer［J］. Lancet, 2019, 393(10167): 169-182.

[11] [11] SAWAYA G F, SMITH-MCCUNE K, KUPPERMANN M. Cervical cancer screening:more choices in 2019［J］. The Journal of the American Medical Association, 2019, 321(20): 2018-2019.

[12] [12] SARFATI D, DYER R, SAM F, et al. Cancer control in the Pacific:big challenges facing small island states［J］. The Lancet Oncology, 2019, 20(9): 475-492.

[13] [13] LIU L, WU N, WANG Y, et al. TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K/AKT oncogenic signaling［J］. Journal of Experimental & Clinical Cancer Research, 2019, 38(1): 106-120.

[14] [14] MANNING B, TOKER A. AKT/PKB signaling:navigating the network［J］. Cell, 2017, 169(3): 381-405.

[15] [15] JANKU F, YAP T, MERIC-BERNSTAM F. Targeting the PI3K pathway in cancer:are we making headway?［J］. Nature Reviews Clinical Oncology, 2018, 15(5): 273-291.

[16] [16] SONG M, BODE A M, DONG Z, et al. AKT as a therapeutic target for cancer［J］. Cancer Research, 2019, 79(6): 1019-1031.

[17] [17] FERNANDEZ L A, SQUATRITO M, NORTHCOTT P, et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation［J］. Oncogene, 2012, 31(15): 1923-1937.

[18] [18] ELSTROM R L, BAUER D E, BUZZAI M, et al. Akt stimulates aerobic glycolysis in cancer cells［J］. Cancer Research, 2004, 64(11): 3892-3899.

[19] [19] GERA J F, MELLINGHOFF I K, SHI Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression［J］. Journal of Biological Chemistry, 2004, 279(4): 2737-2746.